Prisma Health Collaborates with Ethicon, Part of Johnson and Johnson Medical Device Companies

To Manufacture and Distribute the VESper™ Ventilator Expansion Splitter Device that is Authorized for Emergency Use Only During the COVID-19 Pandemic

Prisma Health announced today that it is collaborating with Ethicon Inc., part of the Johnson & Johnson Medical Devices Companies, to make and distribute a ventilator expansion device, called the VESper™ Ventilator Expansion Splitter.

Prisma Health notes the VESper Ventilator Expansion Splitter is authorized for emergency use only to allow a single ventilator to be fitted with the Ventilator Splitter to be used for two rescuable patients for ventilatory support during the COVID-19 pandemic until individual ventilators are available.

Due to the predicted dire ventilator shortage, Prisma Health received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the device in response to the urgency for more ventilators as a result of the pandemic.

Using 3D printing manufacturing technology, Ethicon will manufacture and distribute the VESper Ventilator Expansion Splitter at no cost to healthcare providers in the United States under the EUA during the current COVID-19 pandemic. The initial distribution of the device will be limited to the United States as Prisma Health and Ethicon are developing strategies to navigate various regulatory pathways and fulfill orders worldwide.

“Our goal is to provide healthcare providers with an emergency use device for critical patients in rapid time at no cost,” said Mark O’Halla, Prisma Health president and chief executive officer. “We are pleased to announce this collaboration with Ethicon which brings nationwide scale and expertise for the manufacturing and distribution of VESper by a top-tier medical device company.”

Prisma Health experts are working with national COVID-19 teams, healthcare providers and state and local health authorities to identify healthcare providers where emergency use of the device is needed and will be working closely with these teams to monitor clinical outcomes. Ethicon is bringing its 3D printing manufacturing and supply chain expertise to meet the challenging demand of providing the ventilator expansion splitters.

Healthcare providers interested in the device should complete the request form on www.PrismaHealth.org/VESper. Prisma Health will review all requests so that the device can be  prioritized to areas and hospitals with the greatest need. The VESper Ventilator Expansion Splitter will be packaged a dozen to a box, two required for each patient in accordance with the Instructions for Use that includes the clinical protocol as published online on March 31, 2020 by the U.S. Department of Health & Human Services Assistant Secretary and the U.S Surgeon General titled “Optimizing Ventilator Use During the COVID-19 Pandemic.” The protocol was included in Appendix D: Ventilator Sharing Protocol: Dual-Patient Ventilation with a Single Mechanical Ventilator for Use during Critical Ventilator Shortage. It is critical that this device be used by only trained healthcare providers with relevant expertise where it is deemed clinically appropriate and necessary and only to address the COVID-19 health emergency.

“This collaboration will allow us to have the highest VESper device consistency for healthcare providers in need of treating COVID-19 patients in the United States and beyond,” said Peter Tilkemeier, M.D., chair, Department of Medicine, Prisma Health–Upstate. “We are providing an option to the medical community, reviewed and authorized by the FDA. Each hospital and community needs to decide the best option for them as they begin experiencing ventilator shortages due to COVID-19.”

“Bringing this device to fruition took a village,” said Marjorie Jenkins, M.D., chief academic officer for Prisma Health–Upstate and dean of the University of South Carolina School of Medicine Greenville. “In addition to our founding team of inventors, collaborators and university partners – Clemson University and the University of South Carolina – our sincere compliments to the many, many industry partners who stepped forward during this public health crisis to support us, including Ethicon; Hewlett-Packard Inc. and its Digital Manufacturing Network; Salesforce; AzimuthDS; the Sargent Foundation; and, the FDA Center for Devices and Radiological Health.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”